JP5274826B2 - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- JP5274826B2 JP5274826B2 JP2007321113A JP2007321113A JP5274826B2 JP 5274826 B2 JP5274826 B2 JP 5274826B2 JP 2007321113 A JP2007321113 A JP 2007321113A JP 2007321113 A JP2007321113 A JP 2007321113A JP 5274826 B2 JP5274826 B2 JP 5274826B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- salt
- lysozyme
- water
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 67
- 150000003839 salts Chemical class 0.000 claims description 36
- 108010014251 Muramidase Proteins 0.000 claims description 31
- 102000016943 Muramidase Human genes 0.000 claims description 31
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 31
- 239000004325 lysozyme Substances 0.000 claims description 31
- 235000010335 lysozyme Nutrition 0.000 claims description 31
- 229960000274 lysozyme Drugs 0.000 claims description 31
- 229910052751 metal Inorganic materials 0.000 claims description 18
- 239000002184 metal Substances 0.000 claims description 18
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical group [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 15
- 125000000129 anionic group Chemical group 0.000 claims description 13
- 229920003169 water-soluble polymer Polymers 0.000 claims description 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 239000001110 calcium chloride Substances 0.000 claims description 5
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 235000010418 carrageenan Nutrition 0.000 claims description 5
- 239000000679 carrageenan Substances 0.000 claims description 5
- 229920001525 carrageenan Polymers 0.000 claims description 5
- 229940113118 carrageenan Drugs 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 5
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- SMHNUIFHMAGAFL-UHFFFAOYSA-N calcium;2-hydroxypropanoic acid Chemical compound [Ca].CC(O)C(O)=O SMHNUIFHMAGAFL-UHFFFAOYSA-N 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 35
- 230000000694 effects Effects 0.000 description 18
- -1 sodium halide salts Chemical class 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 14
- 210000000214 mouth Anatomy 0.000 description 13
- 238000004220 aggregation Methods 0.000 description 12
- 230000002776 aggregation Effects 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 238000013329 compounding Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 239000000551 dentifrice Substances 0.000 description 6
- 229960002337 magnesium chloride Drugs 0.000 description 6
- 235000011147 magnesium chloride Nutrition 0.000 description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 5
- 239000001527 calcium lactate Substances 0.000 description 5
- 235000011086 calcium lactate Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 229960002713 calcium chloride Drugs 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 235000010413 sodium alginate Nutrition 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 239000011670 zinc gluconate Substances 0.000 description 4
- 235000011478 zinc gluconate Nutrition 0.000 description 4
- 229960000306 zinc gluconate Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003082 abrasive agent Substances 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- 229940034610 toothpaste Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229940041131 calcium lactate gluconate Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229960003390 magnesium sulfate Drugs 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 2
- 235000013799 ultramarine blue Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- SVIJYLPSHPPVQF-UHFFFAOYSA-N 2-[2,2-diaminoethyl(dodecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCN(CC(N)N)CC(O)=O SVIJYLPSHPPVQF-UHFFFAOYSA-N 0.000 description 1
- HKKXJKUATKEWDT-UHFFFAOYSA-N 2-ethyl-2-(tetradecylamino)butanoic acid Chemical compound C(CCCCCCCCCCCCC)NC(C(=O)O)(CC)CC HKKXJKUATKEWDT-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- VVNANPHBTSDUIH-UHFFFAOYSA-N [5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl acetate Chemical compound CC(=O)OCC1=CN=C(C)C(O)=C1CO VVNANPHBTSDUIH-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 229940059251 calcium bromide Drugs 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium phosphate dihydrate Substances O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940073475 lysozyme hydrochloride Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 229940070802 palmitoyl glutamate Drugs 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 229950005425 sodium myristyl sulfate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- ZNVKGUVDRSSWHV-UHFFFAOYSA-L zinc;4-hydroxybenzenesulfonate Chemical compound [Zn+2].OC1=CC=C(S([O-])(=O)=O)C=C1.OC1=CC=C(S([O-])(=O)=O)C=C1 ZNVKGUVDRSSWHV-UHFFFAOYSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Images
Description
本発明は、口腔用組成物に関し、詳細には、凝縮や沈殿等が起こらず、リゾチーム又はその塩が均一に配合され、かつその活性が安定に維持された口腔用組成物に関する。 The present invention relates to an oral composition, and in particular, relates to an oral composition in which condensation, precipitation, or the like does not occur, lysozyme or a salt thereof is uniformly blended, and its activity is stably maintained.
リゾチームはムコ多糖類加水分解酵素であり、そのムコ多糖類加水分解作用により、炎症を起こす微生物に対して殺菌（溶菌）作用を示し、また、強力な消炎作用を有する。従ってリゾチームは感染症炎症、非感染症炎症のいずれの予防、治療にも有効であり、口腔内疾患、特に歯槽膿漏等の歯周疾患の予防、進行阻止および治療上非常に重要な役割を果たしており、各種の内服剤あるいは外用剤に配合されている。 Lysozyme is a mucopolysaccharide hydrolase, and exhibits a bactericidal (lytic) action against inflamed microorganisms by its mucopolysaccharide hydrolyzing action, and has a strong anti-inflammatory action. Therefore, lysozyme is effective in the prevention and treatment of both infectious and non-infective inflammation, and plays a very important role in the prevention, progression prevention and treatment of oral diseases, especially periodontal diseases such as alveolar pyorrhea. It is used in various internal medicines and external preparations.
このような製剤については、口腔内に適用させるために歯磨剤や洗口剤等の様々なものが挙げられるが、特に口腔内の軟組織（例えば口腔粘膜、舌、歯茎、唾液腺、口蓋など）への適用のしやすさ及び製剤の滞留性を考えた上では指等で塗布できる軟膏状製剤が最も望ましいと思われる。 Examples of such preparations include various products such as dentifrices and mouthwashes for application in the oral cavity, particularly to soft tissues in the oral cavity (eg, oral mucosa, tongue, gums, salivary glands, palate, etc.). Considering the ease of application and the retention of the preparation, an ointment-like preparation that can be applied with a finger or the like is most desirable.
これについて、リゾチーム配合口腔用組成物に関し、リゾチームの活性を高め、またあるいはリゾチームの活性低下を防いで安定配合するために様々な研究が従来よりなされており、種々の特許が開示されている。 In this regard, various studies have been made on lysozyme-blended oral compositions in order to increase the activity of lysozyme and / or prevent the decrease in the activity of lysozyme, and various patents have been disclosed.
例えば、特許文献１（特開昭５２−５４０３７号公報）、特許文献２（特開昭５２−９０６３８号公報）にはハロゲン化ナトリウム塩、特許文献３（特開平０２−２６４７１１号公報）にはリン酸２水素塩、特許文献４（特開平０３−１５７３２２号公報）や特許文献５（特開平０３−１５７３２３号公報）、特許文献６（特開平０３−１６７１１５号公報）には、特定の界面活性剤とリゾチームを共存させた口腔用組成物が開示されている。また、特許文献７（特開平０６−３２９５２３号公報）には、リゾチームにヒドロキシエチルセルロース及びアルギン酸ナトリウムを配合した口腔用組成物が開示されている。 For example, Patent Document 1 (Japanese Patent Laid-Open No. 52-54037), Patent Document 2 (Japanese Patent Laid-Open No. 52-90638) include sodium halide salts, and Patent Document 3 (Japanese Patent Laid-Open No. 02-264711). Dihydrogen phosphate, Patent Document 4 (Japanese Patent Laid-Open No. 03-157322), Patent Document 5 (Japanese Patent Laid-Open No. 03-157323), and Patent Document 6 (Japanese Patent Laid-Open No. 03-167115) have specific interfaces. An oral composition in which an active agent and lysozyme coexist is disclosed. Patent Document 7 (Japanese Patent Laid-Open No. 06-329523) discloses an oral composition in which lysozyme is mixed with hydroxyethyl cellulose and sodium alginate.
しかしながら、これらの口腔用組成物はいずれも歯磨剤や洗口剤を中心とした製剤に関するものであり、これを単純に軟膏状製剤に利用した場合には、外観性状が悪化したり、場合によっては凝集や沈殿を生じるなどする。これは、一般に使用されるラウリル硫酸ナトリウムのようなアニオン性界面活性剤や、カルボキシメチルセルロースナトリウムやアルギン酸ナトリウム、カラギーナンのようなアニオン性水溶性高分子といったイオン性成分にリゾチームが反応することにより、結果として外観性状に影響を及ぼし、凝集や沈殿を生じてしまうためと考えられる。また、上記の口腔用組成物については、実際にリゾチームが組成物全体に均一に配合されているか否かも明らかにされていない。 However, these oral compositions all relate to preparations centering on dentifrices and mouthwashes, and when this is simply used for ointment-like preparations, the appearance properties may deteriorate or in some cases. Causes aggregation and precipitation. This is because lysozyme reacts with ionic components such as commonly used anionic surfactants such as sodium lauryl sulfate and anionic water-soluble polymers such as sodium carboxymethylcellulose, sodium alginate, and carrageenan. It is thought that it affects the appearance properties and causes aggregation and precipitation. In addition, regarding the composition for oral cavity, it has not been clarified whether lysozyme is actually blended uniformly in the entire composition.
そこで本発明者らは、これらの問題を解決すべく、種々検討を行った結果、凝集や沈殿が起こらず、リゾチームが活性を安定に維持したまま組成物中に均一に配合される技術を見出し、さらにはこれが軟膏状製剤をはじめとする口腔用組成物全般に利用できることを見いだして、本発明を完成するに至った。
本発明は、凝縮や沈殿等が起こらず、リゾチーム又はその塩が活性を安定に維持したまま組成物中に均一に配合された口腔用組成物を簡便に提供することを目的とする。 An object of the present invention is to easily provide an oral composition in which lysozyme or a salt thereof is uniformly blended in a composition without causing condensation, precipitation, or the like while maintaining activity stably.
本発明者らは、上記問題を解決すべく鋭意検討を重ねた結果、リゾチーム又はその塩及びアニオン性水溶性高分子に加え、０．５〜１０重量％の水溶性金属塩を配合することにより、凝集や沈殿を引き起こすことなく、組成物中に安定的かつ均一にリゾチーム又はその塩が配合される組成物を作製できることを見出し、本発明を完成させた。 As a result of intensive studies to solve the above problems, the present inventors have added 0.5 to 10% by weight of a water-soluble metal salt in addition to lysozyme or a salt thereof and an anionic water-soluble polymer. The inventors have found that a composition in which lysozyme or a salt thereof is blended stably and uniformly in a composition without causing aggregation or precipitation can be produced, and the present invention has been completed.
すなわち、本発明は、特に以下の項１及び項２の口腔用組成物を提供するものである。
項１．以下の（ａ）〜（ｃ）を配合したことを特徴とする口腔用組成物。
（ａ）リゾチーム又はその塩
（ｂ）カルボキシメチルセルロース塩、キサンタンガム及びカラギーナンからなる群より選択される少なくとも１種のアニオン性水溶性高分子
（ｃ）マグネシウム塩、カルシウム塩及び亜鉛塩からなる群より選択される少なくとも１種の水溶性金属塩を、０．５〜１０重量％
項２．水溶性金属塩が、塩化マグネシウム、塩化カルシウム、乳酸カルシウム及びグルコン酸亜鉛からなる群より選択される少なくとも１種である、項１に記載の口腔用組成物。
That is, this invention provides the composition for oral cavity of the following items 1 and 2 especially.
Item 1. An oral composition comprising the following (a) to (c):
(A) Lysozyme or salt thereof (b) At least one anionic water-soluble polymer selected from the group consisting of carboxymethylcellulose salt, xanthan gum and carrageenan (c) Selected from the group consisting of magnesium salt, calcium salt and zinc salt 0.5 to 10% by weight of at least one water-soluble metal salt
Item 2. Item 2. The oral composition according to Item 1, wherein the water-soluble metal salt is at least one selected from the group consisting of magnesium chloride, calcium chloride, calcium lactate and zinc gluconate.
本発明によれば、凝縮や沈殿等が起こらず、リゾチーム又はその塩が活性を安定に維持したまま組成物中に均一に配合された口腔用組成物を簡便に提供することができる。また、当該口腔用組成物は、リゾチームの活性が安定に維持されているため、口腔内疾患、特に歯槽膿漏等の歯周疾患の予防、進行阻止および治療に好ましく用いることができる。さらに、凝集や沈殿が起こらないため、見た目及び使用時の触感において使用者に不快感を与えることも無く、製造時及び使用時において不都合が生じることも無い。 According to the present invention, it is possible to easily provide an oral composition in which lysozyme or a salt thereof is uniformly blended in the composition while maintaining activity stably without causing condensation or precipitation. Moreover, since the activity of lysozyme is stably maintained, the composition for oral cavity can be preferably used for prevention, progression prevention, and treatment of oral diseases, particularly periodontal diseases such as alveolar pyorrhea. Furthermore, since aggregation and precipitation do not occur, there is no discomfort to the user in appearance and touch during use, and no inconvenience occurs during manufacture and use.
以下、本発明につき更に詳細に説明する。 Hereinafter, the present invention will be described in more detail.
本発明に係る口腔用組成物は、リゾチーム又はその塩、特定のアニオン性水溶性高分子及び水溶性金属塩を配合した口腔用組成物である。 The oral composition according to the present invention is an oral composition containing lysozyme or a salt thereof, a specific anionic water-soluble polymer and a water-soluble metal salt.
リゾチームは、通常鶏卵の卵白から一般的な方法に従って抽出精製することにより得られる。また、市販品として例えばエーザイフード・ケミカル株式会社あるいはキューピー株式会社より入手できる（いずれも商品名は「塩化リゾチーム」）。リゾチームの塩としては、例えば塩化リゾチームが挙げられる。本発明において用いるリゾチーム又はその塩の量は、少なすぎると十分な添加効果を得ることができず、また必要以上過剰に添加することは経済的に不利となる。よって、その添加量は、一般に組成物全量に対して、０．０５〜５．０重量％、好ましくは０．２５〜２．５重量％、より好ましくは０．２５〜１．５重量％である。 Lysozyme is usually obtained by extraction and purification from egg white of chicken eggs according to a general method. Moreover, it can obtain from Eisai Food Chemical Co., Ltd. or Kewpie Co., Ltd. as a commercial item (all are brand names "lysozyme chloride"). Examples of the lysozyme salt include lysozyme chloride. If the amount of lysozyme or a salt thereof used in the present invention is too small, a sufficient addition effect cannot be obtained, and adding more than necessary is economically disadvantageous. Therefore, the addition amount is generally 0.05 to 5.0% by weight, preferably 0.25 to 2.5% by weight, more preferably 0.25 to 1.5% by weight, based on the total amount of the composition. is there.
本発明に係る口腔用組成物に配合されるアニオン性水溶性高分子は、カルボキシメチルセルロース塩、キサンタンガム及びカラギーナンが好ましい。この中でもカルボキシメチルセルロース塩が好ましく、その塩としては、例えばナトリウム塩、カリウム塩、カルシウム塩等が挙げられるが、これらの中でもナトリウム塩であるカルボキシメチルセルロースナトリウムが特に好ましい。また、アニオン性水溶性高分子の配合量は、組成物全量に対し、０．０１〜１０重量％であることが好ましく、０．０５〜５重量％であることがより好ましく、０．５〜２．５重量％であることがさらに好ましく、１〜２重量％であることがよりさらに好ましい。 The anionic water-soluble polymer blended in the oral composition according to the present invention is preferably carboxymethyl cellulose salt, xanthan gum and carrageenan. Among these, carboxymethylcellulose salt is preferable, and examples of the salt include sodium salt, potassium salt, and calcium salt. Among these, sodium salt of carboxymethylcellulose is particularly preferable. Moreover, the compounding amount of the anionic water-soluble polymer is preferably 0.01 to 10% by weight, more preferably 0.05 to 5% by weight, more preferably 0.5 to It is further preferably 2.5% by weight, and more preferably 1 to 2% by weight.
本発明に係る口腔用組成物に配合される水溶性金属塩は、水溶性多価金属塩が好ましく、なかでもマグネシウム塩、カルシウム塩及び亜鉛塩の水溶性多価金属塩が好ましい。具体的には、塩化マグネシウム、リン酸三マグネシウム、硫酸マグネシウム、クエン酸マグネシウム、グルコン酸マグネシウム、塩化カルシウム、グルコン酸カルシウム、乳酸カルシウム、パントテン酸カルシウム、リン酸二水素カルシウム、プロピオン酸カルシウム、酢酸カルシウム、臭化カルシウム、グリセロリン酸カルシウム、塩化亜鉛、グルコン酸亜鉛、パラフェノールスルホン酸亜鉛、硫酸亜鉛、酢酸亜鉛等が例示でき、特に塩化マグネシウム、塩化カルシウム、乳酸カルシウム及びグルコン酸亜鉛が好ましい。これらの水溶性金属塩を用いることで、凝集や沈殿等の発生を抑えるだけでなく、保形性や曵糸性等の製剤学的物性も向上させることができる。また、水溶性金属塩の配合量は、組成物全量に対し、０．５〜１０重量％であることが好ましく、１〜５重量％であることがより好ましく、１〜２．５重量％であることがさらに好ましい。 The water-soluble metal salt to be blended in the composition for oral cavity according to the present invention is preferably a water-soluble polyvalent metal salt, and particularly preferably water-soluble polyvalent metal salts of magnesium salt, calcium salt and zinc salt. Specifically, magnesium chloride, trimagnesium phosphate, magnesium sulfate, magnesium citrate, magnesium gluconate, calcium chloride, calcium gluconate, calcium lactate, calcium pantothenate, calcium dihydrogen phosphate, calcium propionate, calcium acetate , Calcium bromide, calcium glycerophosphate, zinc chloride, zinc gluconate, zinc paraphenolsulfonate, zinc sulfate, zinc acetate and the like, and magnesium chloride, calcium chloride, calcium lactate and zinc gluconate are particularly preferable. By using these water-soluble metal salts, not only the occurrence of aggregation and precipitation can be suppressed, but also the pharmaceutical properties such as shape retention and spinnability can be improved. The amount of the water-soluble metal salt is preferably 0.5 to 10% by weight, more preferably 1 to 5% by weight, and 1 to 2.5% by weight based on the total amount of the composition. More preferably it is.
さらに、本発明に係る口腔用組成物に配合されるアニオン性水溶性高分子と水溶性金属塩の量比は、組成物全量に対する重量％の比が、アニオン性水溶性高分子／水溶性金属塩＝０．０１〜１０であることが好ましく、０．０５〜５であることがより好ましく、０．１〜２であることがさらに好ましい。 Furthermore, the ratio of the anionic water-soluble polymer and the water-soluble metal salt to be blended in the oral composition according to the present invention is such that the ratio by weight to the total amount of the composition is anionic water-soluble polymer / water-soluble metal. The salt is preferably 0.01 to 10, more preferably 0.05 to 5, and further preferably 0.1 to 2.
本発明に係る水溶性の成分は、特に限定されるものではないが、６０℃以上の水に対し０．１重量％以上が溶解するものが好ましい。 The water-soluble component according to the present invention is not particularly limited, but is preferably one in which 0.1% by weight or more dissolves in water at 60 ° C. or higher.
本発明に係る口腔用組成物のｐＨは、本発明の効果を損なわない限り特に限定されるものではないが、リゾチーム活性の安定化をより向上させるため、ｐＨ５〜ｐＨ７であることが好ましい。 Although pH of the composition for oral cavity which concerns on this invention is not specifically limited unless the effect of this invention is impaired, In order to improve the stabilization of lysozyme activity more, it is preferable that it is pH5-pH7.
本発明に係る口腔用組成物は、例えば軟膏状製剤として指等で塗布する、あるいは歯磨剤として歯ブラシにのせる等の使用態様を取ることができる。そのため、チューブ等の容器から絞り出す、あるいは瓶や缶等の容器から指等ですくい取る等して使用することができる。 The composition for oral cavity according to the present invention can be used, for example, by applying with a finger or the like as an ointment-like preparation, or putting it on a toothbrush as a dentifrice. Therefore, it can be used by squeezing out from a container such as a tube, or scooping out a container such as a bottle or can with a finger.
本発明に係る口腔用組成物は、常法に従って例えば軟膏状製剤、練歯磨剤、ジェル剤、パスタ剤、歯磨剤（練歯磨剤、液体歯磨剤、液状歯磨剤等）、洗口剤、ゼリー製剤、ガム剤等の通常の剤形にすることができる。なお、ここで言う軟膏状製剤とは、いわゆる軟膏剤のことをいい、その中には油脂性軟膏、乳剤性軟膏、水溶性軟膏等が含まれる。本発明に係る口腔用組成物は、軟膏状製剤であることが好ましく、その中でも特に水溶性軟膏であることが好ましい。 The composition for oral cavity according to the present invention comprises, for example, ointment preparation, toothpaste, gel, pasta, dentifrice (toothpaste, liquid dentifrice, liquid dentifrice, etc.), mouthwash, jelly according to conventional methods. Ordinary dosage forms such as formulations and gums can be obtained. The ointment-like preparation mentioned here refers to a so-called ointment, and includes an oily ointment, an emulsion ointment, a water-soluble ointment and the like. The oral composition according to the present invention is preferably an ointment-like preparation, and among them, a water-soluble ointment is particularly preferable.
本発明に係る口腔用組成物は、本発明の効果を損なわない限り、他の基剤成分は特に限定するものではなく、通常この種の組成物に用いられるものを配合できる。例えば、軟膏状製剤の場合であれば、湿潤剤、香味剤、活性剤、甘味剤、防腐剤、着色剤、ｐＨ調整剤、安定化剤、矯味剤、収れん剤、増粘剤、他の薬効剤等が適宜配合される。また、練歯磨の場合であれば研磨剤、湿潤剤、香味剤、活性剤、甘味剤、防腐剤、着色剤、ｐＨ調整剤、安定化剤、矯味剤、収れん剤、増粘剤、他の薬効剤等が適宜配合される。 In the composition for oral cavity according to the present invention, other base components are not particularly limited as long as the effects of the present invention are not impaired, and those usually used for this type of composition can be blended. For example, in the case of ointment-like preparations, wetting agents, flavoring agents, active agents, sweeteners, preservatives, coloring agents, pH adjusting agents, stabilizers, flavoring agents, astringents, thickeners, other medicinal properties An agent or the like is appropriately blended. In the case of toothpaste, abrasives, wetting agents, flavoring agents, activators, sweeteners, preservatives, colorants, pH adjusters, stabilizers, flavoring agents, astringents, thickeners, other Medicinal agents and the like are appropriately blended.
具体的には、湿潤剤として、エタノール、グリセリン、ソルビット、エチレングリコール、プロピレングリコール、１，３−ブチレングリコール、ポリエチレングリコール、ポリプロピレングリコール、キシリトール、マルチトール、ラクチトール、パラチニット等を単独または２種以上を組み合わせて配合することができる。湿潤剤の通常配合量は、５〜７０重量％である。 Specifically, as a wetting agent, ethanol, glycerin, sorbit, ethylene glycol, propylene glycol, 1,3-butylene glycol, polyethylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, palatinit, etc. alone or in combination It can mix | blend in combination. The normal amount of wetting agent is 5 to 70% by weight.
香味剤としては、メントール、アネトール、カルボン、オイゲノール、リモネン、ペパーミントオイル、スペアミントオイル、ウインターグリーン、サリチル酸メチル、シオネール、チモール、丁字油、ユーカリ油、ローズマリー油、セージ油、レモン油、オレンジ油、オシメン油、シトロネロール、メチルオイゲノール等が挙げられる。これらの香味剤は、単独または２種以上を組み合わせて配合することができる。香味剤の通常配合量は、０．０５〜５重量％である。 As a flavoring agent, menthol, anethole, carvone, eugenol, limonene, peppermint oil, spearmint oil, winter green, methyl salicylate, shioneer, thymol, clove oil, eucalyptus oil, rosemary oil, sage oil, lemon oil, orange oil, Osimene oil, citronellol, methyl eugenol and the like can be mentioned. These flavoring agents can be blended alone or in combination of two or more. The usual compounding quantity of a flavoring agent is 0.05 to 5 weight%.
活性剤としては、ラウリル硫酸ナトリウム、ミリスチル硫酸ナトリウム等のアルキル硫酸ナトリウム、Ｎ−パルミトイルグルタミン酸ナトリウム等のＮ−アシルグルタミン酸塩、ショ糖脂肪酸エステル、マルトース脂肪酸エステル、ラクトース脂肪酸エステル等の糖脂肪酸エステル、ポリオキシエチレンアルキルエーテル類、アルキルグルコシド類、脂肪酸アルカノールアミド類、ポリオキシエチレンソルビタンモノラウレート、ポリオキシエチレンソルビタンモノステアレート等のポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油、ソルビタン脂肪酸エステル、脂肪酸モノグリセライド、Ｎ−ラウリルジアミノエチルグリシン、Ｎ−ミリスチルジエチルグリシン等のＮ−アルキルジアミノエチルグリシン、Ｎ−アルキル−Ｎ−カルボキシメチルアンモニウムベタイン、ラウリルジメチルアミノ酢酸ベタイン等の界面活性剤が挙げられる。これらの界面活性剤は、単独または２種以上を組み合わせて配合でき、通常配合量は０．１〜１０重量％である。 Activating agents include sodium alkyl sulfates such as sodium lauryl sulfate and sodium myristyl sulfate, N-acyl glutamates such as sodium N-palmitoyl glutamate, sucrose fatty acid esters, maltose fatty acid esters, sugar fatty acid esters such as lactose fatty acid esters, poly Oxyethylene alkyl ethers, alkyl glucosides, fatty acid alkanolamides, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monostearate, polyoxyethylene hydrogenated castor oil, sorbitan fatty acid esters, Fatty acid monoglyceride, N-alkyldiaminoethylglycine such as N-lauryldiaminoethylglycine, N-myristyldiethylglycine, - alkyl -N- carboxymethyl ammonium betaine surfactants such as lauryl dimethylamino acetic acid betaine. These surfactants can be blended singly or in combination of two or more, and the blending amount is usually 0.1 to 10% by weight.
甘味剤として、サッカリンナトリウム、アセスルファームカリウム、ステビオサイド、ネオヘスペリジルジヒドロカルコン、グリチルリチン、ペリラルチン、タウマチン、アスパラチルフェニルアラニルメチルエステル、α−メトキシシンナミックアルデヒド、キシリット、スクラロース、キシリトール、パラチノース、パラチニット、エリスリトール、マルチトール等を配合することができる。これらの甘味剤は、単独または２種以上を組み合わせて配合することができる。甘味剤の通常配合量は０．００５〜５重量％、好ましくは０．０１〜０．５重量％である。 As sweeteners, saccharin sodium, acesulfame potassium, stevioside, neohesperidyl dihydrochalcone, glycyrrhizin, perilartine, thaumatin, asparatylphenylalanyl methyl ester, α-methoxycinnamic aldehyde, xylit, sucralose, xylitol, palatinose, palatinit, Erythritol, maltitol, etc. can be blended. These sweeteners can be blended alone or in combination of two or more. The usual amount of sweetener is 0.005 to 5% by weight, preferably 0.01 to 0.5% by weight.
防腐剤としては、メチルパラベン、エチルパラベン、プロピルパラベン、ブチルパラベン等のパラベン類、安息香酸ナトリウム、フェノキシエタノール、塩酸アルキルジアミノエチルグリシン等が挙げられる。 Examples of the preservative include parabens such as methyl paraben, ethyl paraben, propyl paraben, and butyl paraben, sodium benzoate, phenoxyethanol, and alkyldiaminoethylglycine hydrochloride.
着色剤としては、青色１号、黄色４号、赤色２０２号、緑３号等の法定色素、群青、強化群青、紺青等の鉱物系色素、酸化チタン等が挙げられる。 Examples of the colorant include legal dyes such as Blue No. 1, Yellow No. 4, Red No. 202, and Green No. 3, mineral dyes such as ultramarine blue, enhanced ultramarine blue, and bitumen, and titanium oxide.
ｐＨ調整剤としては、クエン酸、リン酸、リンゴ酸、ピロリン酸、乳酸、酒石酸、グリセロリン酸、酢酸、硝酸、またはこれらの化学的に可能な塩や水酸化ナトリウム等が挙げられ、これらは、組成物のｐＨが５〜７の範囲となるよう、単独または２種以上を組み合わせて配合することができる。ｐＨ調整剤の通常配合量は０．０１〜２重量％である。 Examples of the pH adjuster include citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or a chemically possible salt thereof, sodium hydroxide, and the like. It can mix | blend individually or in combination of 2 or more types so that pH of a composition may be the range of 5-7. The normal amount of the pH adjuster is 0.01 to 2% by weight.
安定化剤としては、エデト酸ナトリウム、チオ硫酸ナトリウム、亜硫酸ナトリウム、塩化ナトリウム、乳酸カルシウム、ラノリン、トリアセチン、ヒマシ油、硫酸マグネシウム等が挙げられる。 Examples of the stabilizer include sodium edetate, sodium thiosulfate, sodium sulfite, sodium chloride, calcium lactate, lanolin, triacetin, castor oil, magnesium sulfate and the like.
矯味剤としては、チャエキス、チャ乾留液、プロポリスエキス、グルタミン酸ナトリウム等が挙げられる。 Examples of the corrigent include tea extract, tea dry distillation solution, propolis extract, sodium glutamate and the like.
収れん剤としては、重曹、乳酸アルミニウム等が挙げられる。 Examples of astringents include baking soda and aluminum lactate.
増粘剤として、本発明に用いるカルボキシメチルセルロース塩以外に、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシエチルセルロース等のセルロース誘導体、本発明に用いるキサンタンガム以外に、トラガカントガム、カラヤガム、アラビアガム、ジェランガム等のガム類、ポリビニルアルコール、ポリアクリル酸ナトリウム、カルボキシビニルポリマー、ポリビニルピロリドン等の合成粘結剤、増粘性シリカ、アルミニウムシリカゲル、ビーガム等の無機粘結剤、アルギン酸ナトリウム、ペクチン、大豆多糖類、コンドロイチン硫酸ナトリウム、ヒアルロン酸ナトリウム等を添加することも可能である。これらの増粘剤は、単独または２種以上を組み合わせて配合することができる。増粘剤の通常配合量は０．０１〜２０重量％である。 As a thickener, in addition to the carboxymethylcellulose salt used in the present invention, cellulose derivatives such as hydroxypropylcellulose, hydroxypropylmethylcellulose, and hydroxyethylcellulose; in addition to xanthan gum used in the present invention, gums such as tragacanth gum, karaya gum, gum arabic, and gellan gum , Synthetic binders such as polyvinyl alcohol, sodium polyacrylate, carboxyvinyl polymer, polyvinylpyrrolidone, inorganic binders such as thickening silica, aluminum silica gel, bee gum, sodium alginate, pectin, soybean polysaccharide, sodium chondroitin sulfate, It is also possible to add sodium hyaluronate or the like. These thickeners can be blended alone or in combination of two or more. The normal blending amount of the thickener is 0.01 to 20% by weight.
他の薬効剤としては、フッ化ナトリウム、モノフルオロリン酸ナトリウム、フッ化第一錫等のフッ素化合物；デキストラナーゼ、ムタナーゼ、アミラーゼ、プロテアーゼ、溶菌酵素（リテックエンザイム）等の酵素；トラネキサム酸、ε−アミノカプロン酸、アルミニウムクロルヒドロキシアラントイン、アラントイン、ジヒドロコレステロール、グリチルリチン酸類、グリチルレチン酸、ビサボロール、イソプロピルメチルフェノール、グリセロリン酸、クロロフィル、グルコン酸銅、塩化ナトリウム、水溶性無機リン酸化合物、クロルヘキシジン塩類、トリクロサン、塩化セチルピリジニウム、塩化ベンザルコニウム、塩化ベンゼトニウム；酢酸−ｄｌ−α−トコフェロール、酢酸ピリドキシン、アスコルビン酸またはその塩等のビタミン類；タイム、オウゴン等の植物抽出物等が挙げられる。これらの薬効剤は、単独または２種以上を組み合わせて配合することができる。 Other medicinal agents include: fluorine compounds such as sodium fluoride, sodium monofluorophosphate, stannous fluoride; enzymes such as dextranase, mutanase, amylase, protease, lytic enzyme (Litech Enzyme); tranexamic acid, ε-aminocaproic acid, aluminum chlorohydroxy allantoin, allantoin, dihydrocholesterol, glycyrrhizic acid, glycyrrhetinic acid, bisabolol, isopropylmethylphenol, glycerophosphoric acid, chlorophyll, copper gluconate, sodium chloride, water-soluble inorganic phosphate compound, chlorhexidine salts, triclosan , Cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride; vitamins such as acetic acid-dl-α-tocopherol, pyridoxine acetate, ascorbic acid or salts thereof Kinds: plant extracts such as thyme and urgon are listed. These medicinal agents can be blended alone or in combination of two or more.
研磨剤としては、第２リン酸カルシウム・２水和物および無水和物、リン酸カルシウム、第３リン酸カルシウム、炭酸カルシウム、ピロリン酸カルシウム、水酸化アルミニウム、アルミナ、無水ケイ酸、シリカゲル、ケイ酸アルミニウム、不溶性メタリン酸ナトリウム、第３リン酸マグネシウム、炭酸マグネシウム、硫酸カルシウム、ポリメタクリル酸メチル、ベントナイト、ケイ酸ジルコニウム、ハイドロキシアパタイト、合成樹脂等を用いることができる。これらの研磨剤は単独で用いても、２種以上を併用してもよい。研磨剤の通常配合量は、５〜５０重量％である。 As abrasives, dicalcium phosphate dihydrate and anhydrous, calcium phosphate, tricalcium phosphate, calcium carbonate, calcium pyrophosphate, aluminum hydroxide, alumina, anhydrous silicic acid, silica gel, aluminum silicate, insoluble sodium metaphosphate Tertiary magnesium phosphate, magnesium carbonate, calcium sulfate, polymethyl methacrylate, bentonite, zirconium silicate, hydroxyapatite, synthetic resin, and the like can be used. These abrasives may be used alone or in combination of two or more. The normal compounding amount of the abrasive is 5 to 50% by weight.
また、その他の基剤として、アルコール類、シリコン、アパタイト、白色ワセリン、パラフィン、流動パラフィン、マイクロクリスタリンワックス、スクワラン等を添加することも可能である。 As other bases, alcohols, silicon, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane and the like can be added.
なお、これら任意成分の配合量は、本発明の効果を妨げない程度で、通常の口腔用組成物に配合されている程度の量とすればよい。 In addition, what is necessary is just to let the compounding quantity of these arbitrary components be the quantity of the grade mix | blended with the normal composition for oral cavity, as long as the effect of this invention is not prevented.
以下、実施例及び比較例を示して本発明を具体的に説明するが、本発明は下記実施例に限定されるものではない。なお、各例中の配合量は、特に規定がない限り重量％を示す。 EXAMPLES Hereinafter, although an Example and a comparative example are shown and this invention is demonstrated concretely, this invention is not limited to the following Example. In addition, the compounding quantity in each example shows weight%, unless there is a prescription | regulation.
＜組成物の調製＞
各種金属塩に水及びメチルパラベンを加え、６０〜７０℃に加熱し、溶解するまで５〜１０分間撹拌を行った。次に、濃グリセリン及び各種アニオン性水溶性高分子を加え、ホモミキサー（Ｍ２−ｆ、特殊機化工業株式会社製）で３０００ｒｐｍにて５分間撹拌を行った。さらに、水及び塩化リゾチームを加え、ホモミキサーで３０００ｒｐｍにて５分間撹拌を行って水溶性軟膏剤を作製した。
<Preparation of composition>
Water and methyl paraben were added to various metal salts, heated to 60 to 70 ° C., and stirred for 5 to 10 minutes until dissolved. Next, concentrated glycerin and various anionic water-soluble polymers were added, and the mixture was stirred for 5 minutes at 3000 rpm with a homomixer (M2-f, manufactured by Tokushu Kika Kogyo Co., Ltd.). Further, water and lysozyme chloride were added, and the mixture was stirred with a homomixer at 3000 rpm for 5 minutes to prepare a water-soluble ointment.
＜組成物の性能評価＞
各例において、製造した組成物の凝集性及び外観性状を評価した。
<Performance evaluation of composition>
In each example, the cohesiveness and appearance properties of the produced compositions were evaluated.
凝集性
凝集が発生（粒状のものが複数生成された状態のものも含む）したか否かを目視により評価した。評価基準については以下の通りである。
○：凝集の発生が認められなかったもの
×：凝集が発生したもの
Aggregation property It was visually evaluated whether or not aggregation occurred (including a state where a plurality of granular materials were produced). The evaluation criteria are as follows.
○: No aggregation was observed ×: Aggregation occurred
外観性状
当該組成物が口腔用組成物として使用されるものであることを考慮した上で、凝集・沈殿等の発生や色等を目視により総合的に評価した。評価基準については以下の通りである。
１：外観性状が非常に良いもの
２：外観性状が良いもの
３：外観性状が悪いもの
Appearance properties In consideration of the fact that the composition is used as an oral composition, the occurrence and color of aggregation / precipitation and the like were evaluated comprehensively visually. The evaluation criteria are as follows.
1: Appearance property is very good 2: Appearance property is good 3: Appearance property is bad
以下に、組成物調製時の配合量及び組成物の性能評価の結果を記載した表を示す。なお、表中の成分についての数値は、その配合量を重量％で表したものである。 Below, the table | surface which described the compounding quantity at the time of composition preparation and the result of the performance evaluation of a composition is shown. In addition, the numerical value about the component in a table | surface represents the compounding quantity in weight%.
表１に示した通り、実施例の結果から、カルボキシメチルセルロースナトリウム、キサンタンガム及びカラギーナンからなる群より選択されるアニオン性水溶性高分子を１〜２％、並びに、塩化マグネシウム、塩化カルシウム、乳酸カルシウム及びグルコン酸亜鉛からなる群より選択される少なくとも１種の水溶性金属塩を０．５〜１０％含む組成物は、凝集がなく、外観性状も良好であることが確認された。 As shown in Table 1, from the results of Examples, 1-2% of an anionic water-soluble polymer selected from the group consisting of sodium carboxymethylcellulose, xanthan gum and carrageenan, and magnesium chloride, calcium chloride, calcium lactate and The composition containing 0.5 to 10% of at least one water-soluble metal salt selected from the group consisting of zinc gluconate was confirmed to have no aggregation and good appearance properties.
これに対して、比較例１〜４の結果から、水溶性金属塩の濃度が０．１％以下では、凝縮が起こり、外観性状も悪いことが確認された。また、比較例５〜１１の結果から、アニオン性水溶性高分子としてアルギン酸ナトリウムは不適であることが確認された。さらに、比較例１２〜１４の結果から、金属塩としてリン酸水素カルシウム、炭酸カルシウム、乳酸アルミニウムを用いたのでは凝縮が発生し、外観性状も悪いことが確認された。 On the other hand, from the results of Comparative Examples 1 to 4, it was confirmed that when the concentration of the water-soluble metal salt was 0.1% or less, condensation occurred and the appearance properties were poor. Moreover, from the results of Comparative Examples 5 to 11, it was confirmed that sodium alginate was unsuitable as an anionic water-soluble polymer. Further, from the results of Comparative Examples 12 to 14, it was confirmed that condensation occurred and the appearance properties were poor when calcium hydrogen phosphate, calcium carbonate, or aluminum lactate was used as the metal salt.
以上のように、特定のアニオン性水溶性高分子及び特定の水溶性金属塩を、それぞれ特定の濃度配合することで、初めて本願発明に係る口腔用組成物の効果が発揮されることがわかった。 As described above, it was found that the effect of the composition for oral cavity according to the present invention was exhibited for the first time by blending a specific anionic water-soluble polymer and a specific water-soluble metal salt with specific concentrations. .
＜組成物中のリゾチーム活性評価＞
実施例１及び４並びに比較例２の組成物における、塩化リゾチームの活性を測定した。組成物調製は測定前日に行い、日本薬局方外医薬品成分規格のリゾチーム塩酸塩定量法に従って測定した。なお、測定は同一組成物の３点から試料を回収して行った。
以下に、その結果を示す。また、当該結果をグラフ化したものを図１に示す。
<Evaluation of lysozyme activity in the composition>
The activity of lysozyme chloride in the compositions of Examples 1 and 4 and Comparative Example 2 was measured. The composition was prepared on the day before the measurement, and was measured according to the lysozyme hydrochloride quantification method of the Japanese Pharmacopoeia Standards for Pharmaceutical Components. The measurement was performed by collecting samples from three points of the same composition.
The results are shown below. A graph of the results is shown in FIG.
表２に示した通り、塩化マグネシウムを１０％配合した組成物（実施例１）及び１％配合した組成物（実施例４）は、いずれもリゾチーム活性はほぼ１００％に保たれていた。さらに標準偏差も、両方ともに０．７と低値であり、組成物中にほぼ均一にリゾチームが配合されていることがわかった。これに対して、塩化マグネシウムを加えなかった組成物（比較例２）では、リゾチーム活性が１０％程度低下し、さらに標準偏差が８．０であり、リゾチーム配合の均一性を著しく欠くことがわかった。 As shown in Table 2, the lysozyme activity of the composition containing 10% magnesium chloride (Example 1) and the composition containing 1% (Example 4) was maintained at almost 100%. Furthermore, the standard deviations were both as low as 0.7, and it was found that lysozyme was blended almost uniformly in the composition. On the other hand, in the composition to which no magnesium chloride was added (Comparative Example 2), the lysozyme activity was reduced by about 10%, and the standard deviation was 8.0. It was.
以下に、本発明に係る口腔用組成物の処方例を記載する。 Below, the formulation example of the composition for oral cavity which concerns on this invention is described.
Claims (2)
（ａ）リゾチーム又はその塩
（ｂ）カルボキシメチルセルロース塩、キサンタンガム及びカラギーナンからなる群より選択される少なくとも１種のアニオン性水溶性高分子
（ｃ）マグネシウム塩及びカルシウム塩からなる群より選択される少なくとも１種の水溶性金属塩を、０．５〜１０重量％ An oral composition comprising the following (a) to (c):
(A) lysozyme or a salt thereof (b) carboxymethyl cellulose salt is selected from at least one anionic water-soluble polymer (c) magnesium and calcium salts or Ranaru group selected from the group consisting of xanthan gum and carrageenan 0.5 to 10% by weight of at least one water-soluble metal salt
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007321113A JP5274826B2 (en) | 2007-12-12 | 2007-12-12 | Oral composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007321113A JP5274826B2 (en) | 2007-12-12 | 2007-12-12 | Oral composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009143831A JP2009143831A (en) | 2009-07-02 |
| JP5274826B2 true JP5274826B2 (en) | 2013-08-28 |
Family
ID=40914893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007321113A Expired - Fee Related JP5274826B2 (en) | 2007-12-12 | 2007-12-12 | Oral composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5274826B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6005967B2 (en) * | 2012-03-29 | 2016-10-12 | 株式会社コーセー | UV protection cosmetics |
| CN109528498B (en) * | 2018-12-30 | 2021-05-18 | 美釉(西安)生物技术有限公司 | A tooth desensitizer for deeply occluding dental tubules and preventing biofilm formation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH085800B2 (en) * | 1986-12-19 | 1996-01-24 | エーザイ株式会社 | Aqueous formulation containing lysozyme chloride and dipotassium glycyrrhizinate |
| JPH0426630A (en) * | 1990-05-19 | 1992-01-29 | Wakiyou Kagaku Kogyo Kk | Stabilization of lysozyme salt in aqueous formulation |
| JPH07196463A (en) * | 1993-12-28 | 1995-08-01 | Lion Corp | Composition for oral cavity |
| JP2000281562A (en) * | 1999-03-30 | 2000-10-10 | Taisho Pharmaceut Co Ltd | Gel-like composition |
| JP4377024B2 (en) * | 2000-03-31 | 2009-12-02 | 日本ゼトック株式会社 | Oral composition |
| JP2002029950A (en) * | 2000-07-14 | 2002-01-29 | Lion Corp | Zinc compound-containing composition for oral cavity |
-
2007
- 2007-12-12 JP JP2007321113A patent/JP5274826B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009143831A (en) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5684454B2 (en) | Oral care therapeutic and prophylactic compositions | |
| RU2452465C2 (en) | Dental compositions for xerostomia | |
| WO2016031461A1 (en) | Oral composition for alleviation of dentin hypersensitivity | |
| RU2455001C2 (en) | Compositions and methods of treating xerostomia | |
| US20070098650A1 (en) | Dental formulation | |
| US20130017237A1 (en) | Antiplaque oral care compositions | |
| JP2019052110A (en) | Oral composition | |
| JP4261744B2 (en) | Oral composition | |
| JP5730025B2 (en) | Oral composition | |
| JPH1112142A (en) | Oral composition | |
| JP2002179541A (en) | Composition for oral cavity containing cationic disinfectant | |
| WO2018066341A1 (en) | Oral composition and method for suppressing discoloration of formulation and liquid separation thereof | |
| JP5274826B2 (en) | Oral composition | |
| JP2012012303A (en) | Oral composition | |
| JPH0436228A (en) | Composition for oral cavity application | |
| JPH1045550A (en) | Oral hygiene-promoting composition | |
| EP3217951B1 (en) | Oral care composition | |
| JPH08268851A (en) | Composition for oral cavity | |
| JPH11130648A (en) | Composition for oral cavity | |
| JPH06239723A (en) | Composition for oral cavity | |
| JP3821037B2 (en) | Periodontal pathogen adhesion inhibitor and composition for oral cavity having periodontal pathogen adhesion inhibitory action | |
| JP6734090B2 (en) | Oral composition | |
| JP3877412B2 (en) | Liquid oral composition | |
| JP2002020254A (en) | Dentifrice preparation composition | |
| JP2011073970A (en) | Composition for oral cavity or throat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101125 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120321 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120612 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120727 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130423 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130515 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5274826 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |